All results

9 results for phase 2 multi center double blind randomized dose ranging placebo controlled study

• Edgewise-210

  The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…

  Ages

  4 Years - 9 Years

  Sexes

  Male

• Protocol TN-28

  A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of…

  Ages

  12 Years - 34 Years

  Sexes

  All

• PROTECT Extension Study

  The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…

  Ages

  9 Years - 19 Years

  Sexes

  All

• Efficacy and Safety of AMG 570 in Subjects With Active SLE

  The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…

  Ages

  18 Years - 75 Years

  Sexes

  All

• IMPALA-2

  160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…

  Ages

  18 Years - N/A

  Sexes

  All

• TN-31 JAKPOT T1D

  A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…

  Ages

  12 Years - 35 Years

  Sexes

  All

• GCAptAIN

  This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…

  Ages

  50 Years - N/A

  Sexes

  All

• Mino-Lok

  This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that…

  Ages

  12 Years - N/A

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All